Growth Metrics

Odyssey Health (ODYY) R&D In Process (2021 - 2023)

Odyssey Health's quarterly R&D In Process came in at $170000.0 in Q1 2023, down 98.2% quarter-over-quarter from $9.4 million in Q2 2021.

Odyssey Health has reported R&D In Process for 2 years, with the latest figure at $170000.0 in Q1 2023.

  • For the quarter ending Q1 2023, R&D In Process changed N/A year-over-year to $170000.0; the trailing twelve-month figure through Jan 2023 stood at $170000.0 (down 98.2% YoY), and the FY2021 full-year result was $9.4 million, changed N/A from the prior year.
  • R&D In Process for Q1 2023 stood at $170000.0, down from $9.4 million in the prior quarter.
  • The five-year high for R&D In Process was $9.4 million in Q2 2021, with the low at $170000.0 in Q1 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D In Process (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn -
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -
10 Odyssey Health - - - -

Historic Data

Download Data 🔒
DateValue
Jan 31, 2023 170,000.00
Apr 30, 2021 9.44 Mn